Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Rhea-AI Summary

Cybin, a clinical-stage biopharmaceutical company focused on next-generation psychedelic treatments for mental health, announced that CEO Doug Drysdale will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference. The event is scheduled for June 27, 2024, and Drysdale's fireside chat will be available on demand starting at 7:00 a.m. ET. The webcast can be accessed via a link provided in the announcement and will be archived on Cybin's investor relations website.

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference, taking place June 27, 2024.

Mr. Drysdale’s fireside chat will be available on demand beginning on Thursday, June 27, 2024, at 7:00 a.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.

About Cybin

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.

Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.

Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240619694356/en/

Investor & Media Contact:

Gabriel Fahel

Chief Legal Officer

Cybin Inc.

1-866-292-4601

irteam@cybin.com – or – media@cybin.com

Source: Cybin Inc.

FAQ

When will Cybin participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference?

Cybin will participate in the conference on June 27, 2024.

What time will Doug Drysdale's fireside chat be available at the Neuro Perspectives Virtual Conference?

Doug Drysdale's fireside chat will be available on demand starting at 7:00 a.m. ET on June 27, 2024.

Where can I access the webcast for Cybin's participation in the Neuro Perspectives Virtual Conference?

The webcast can be accessed via a link provided in the announcement and will also be available on Cybin's investor relations website.

What is the stock symbol for Cybin?

Cybin's stock symbols are NYSE American:CYBN and Cboe CA:CYBN.

Who is the CEO of Cybin?

Doug Drysdale is the CEO of Cybin.